Novel approaches to inhibitor design for the p110β phosphoinositide 3-kinase

Hashem A. Dbouk, Jonathan M. Backer

Research output: Contribution to journalReview article

7 Scopus citations

Abstract

Phosphoinositide (PI) 3-kinases are essential regulators of cellular proliferation, survival, metabolism, and motility that are frequently dysregulated in human disease. The design of inhibitors to target the PI 3-kinase/mTOR pathway is a major area of investigation by both academic laboratories and the pharmaceutical industry. This review focuses on the Class IA PI 3-kinase p110β, which plays a unique role in thrombogenesis and in the growth of tumors with deletion or loss-of-function mutation of the Phosphatase and Tensin Homolog (PTEN) lipid phosphatase. Several p110β-selective inhibitors that target the ATP-binding site in the kinase domain have been identified. However, recent discoveries regarding the regulatory mechanisms that control p110β activity suggest alternative strategies by which to disrupt signaling by this PI 3-kinase isoform. This review summarizes the current status of p110β-specific inhibitors and discusses how these new insights into p110 regulation might be used to devise novel pharmacological inhibitors.

Original languageEnglish (US)
Pages (from-to)149-153
Number of pages5
JournalTrends in Pharmacological Sciences
Volume34
Issue number3
DOIs
StatePublished - Mar 1 2013

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology

Fingerprint Dive into the research topics of 'Novel approaches to inhibitor design for the p110β phosphoinositide 3-kinase'. Together they form a unique fingerprint.

  • Cite this